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Bone metastases occur in more than one-third of patients with advanced lung cancer and 
are difficult to treat. We previously demonstrated the therapeutic effect of a third generation 
bisphosphonate (BP), minodronate, and anti-parathyroid hormone-related protein (PTHrP) 
neutralizing antibody (PTHrP Ab) on bone metastases induced by the human small cell lung 
cancer (SCLC) cell line, SBC-5, in natural killer (NK)-cell depleted SCID mice. The purpose 
of our current study was to examine the effect of the combination of PTHrP Ab and 
zoledronic acid (ZOL), which has been approved to treat bone metastases, against bone 
metastases produced by SBC-5 cells expressing PTHrP. Treatment with PTHrP Ab and/or 
ZOL did not affect the proliferation of SBC-5 cells in vitro. Repeated treatments with either 
PTHrP Ab or ZOL inhibited the formation of osteolytic bone metastases of SBC-5 cells, but 
had no effect on metastases to visceral organs. Importantly, combined treatment with PTHrP 
Ab and ZOL further inhibited the formation of bone metastases. Histological assays showed 
that, compared with either PTHrP Ab or ZOL alone, their combination decreased the number 
of tumor associated osteoclasts and increased the number of apoptotic tumor cells. These 
findings suggest that this novel dual targeting therapy may be useful for controlling bone 
metastases in a subpopulation of SCLC patients. 
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Introduction 
Lung cancer is the most common cause of cancer deaths in the world, with more than 
60,000 patients newly diagnosed per year in Japan. Lung cancer frequently metastasizes to 
systemic lymph nodes and distant organs, and >90% of deaths from lung cancer can be 
attributed to metastases (1). Bone is the third most common metastatic organ in lung cancer 
patients, with bone metastases occurring in more than one-third of patients with advanced 
lung cancer. These metastases can cause bone pain, hypercalcemia, nerve compression 
syndromes, and even fractures, and can decrease patient quality of life (2). Although 
skeletal complications can be managed locally by surgery or radiotherapy or systemically 
with chemotherapy and analgesics, these treatments are not sufficient for improving patient 
prognosis. 
The formation of bone metastases is a multi-step event, regulated not only by 
cancer cells but also by host microenvironments.  Of cells in the host microenvironment, 
osteoclasts are regarded as playing critical roles.  Osteoclasts cause bone resorption, 
which provides the spaces in which cancer cells grow, as well as releasing various growth 
factors from bone matrix (3, 4). These findings suggest that osteoclasts may be ideal 
therapeutic targets for the inhibition of osteolytic bone metastases. Bisphosphonates (BPs) 
are hydrolysis-resistant PP1 derivatives that have a high affinity for bone and block the 
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mevalonate pathway, resulting in apoptosis of osteoclasts and inhibiting osteoclastic bone 
resorption (5). Several BPs have been used recently to treat osteoporosis and 
hypercalcemia (6). In addition, we have shown that a third generation nitrogen-containing 
bisphosphonate, minodronate (YM529), could inhibit the growth of bone metastases 
produced by the SBC-5 human small cell lung cancer (SCLC) cell line in severe combined 
immunodeficient (SCID) mice (7). Zoledronic acid (ZOL) is another third-generation BP that 
has demonstrated superior efficacy, compared with pamidronate, in the treatment of 
hypercalcemia of malignancy (8). A phase III, randomized, placebo-controlled trial has 
shown that ZOL reduced the proportion of lung cancer patients with skeletal-related events 
(SREs) (9). Although ZOL has been approved for the treatment of bone metastases in 
patients with multiple myeloma and other solid tumors, including breast and lung cancer (10), 
ZOL delayed SREs only by 2 months when combined with conventional chemotherapy, and 
it could not improve the survival of advanced lung cancer patients with bone metastases (9, 
11, 12). 
Parathyroid hormone-related protein (PTHrP) has a 70% homology to the first 13 
amino acids of the N-terminal protein of PTH (13). PTHrP, which was originally identified as 
a 17-kDa PTH-like adenylate cyclase-stimulating protein from a tumor associated with 
humoral hypercalcemia of malignancy (HHM) (14), has been shown to enhance osteoclast 
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formation and bone destruction in malignant diseases. Moreover, this protein is 
overexpressed by many tumor cell types, including those of breast, prostate and lung cancer 
(15). The importance of PTHrP to the development and progression of bone metastases has 
been shown in several rodent models of bone metastasis, including those from breast, 
prostate, and lung cancer (14, 16, 17). We previously established a bone metastasis model 
with multiple-organ dissemination using the human SCLC cell line, SBC-5, which 
overexpresses PTHrP, in natural killer (NK) cell-depleted SCID mice (18). Using this model, 
we found that anti-PTHrP neutralizing antibody (PTHrP Ab) successfully inhibited the 
production of osteolytic bone metastases of SBC-5 cells (14). The goal of our research is to 
establish more effective therapeutic modalities against lung cancer bone metastases. We 
therefore investigated the effect of the combination of PTHrP Ab (targeting PTHrP) and ZOL 
(targeting osteoclasts) in our bone metastasis model of SBC-5 cells in NK-cell depleted 
SCID mice.  
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Materials and methods 
Cell lines and culture conditions 
The SBC-5 human small cell lung cancer cell line was the kind gift of Drs. M. Tanimoto and 
K. Kiura (Okayama University, Okayama, Japan) (18). These cells were cultured in RPMI 
1640 medium, supplemented with 10% fetal bovine serum (FBS), penicillin (100 U/ml), and 
streptomycin (50 μg/ml), in a humidified CO2 incubator at 37°C. 
 
Reagents 
Anti-mouse IL-2 receptor β chain monoclonal Ab, TM- β1 (IgG2b), was kindly supplied by 
Drs. M. Miyasaka and T. Tanaka (Osaka University, Osaka, Japan) (19). A murine 
monoclonal Ab directed against PTHrP-(1-34) was kindly supplied from by Chugai 
Pharmaceutical Co. (Shizuoka, Japan) (20), and ZOL was purchased from Novartis 
Pharmaceuticals (East Hanover, NJ).  
 
In Vitro Effect of anti-PTHrP Ab and/or ZOL on proliferation of SBC-5 Cells 
SBC-5 cells at 80% confluence were harvested, seeded at 2 x 103 cells per well in 96-well 
plates, and incubated in RPMI 1640 for 24 h. Various concentrations of anti-PTHrP Ab 
and/or ZOL were added,  the cultures were incubated for 72 h at 37°C, a 50 μL aliquot of 
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3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide solution (2 mg/mL; Sigma, St. 
Louis, MO) was added to each well and the cells were incubated for 2 h at 37°C (21). The 
media were removed and the dark blue crystals in each well were dissolved in 100 μL 
DMSO. Absorbance was measured with an MTP-120 microplate reader (Corona Electric, 
Ibaraki, Japan) at test and reference wavelengths of 550 nm and 630 nm, respectively. Data 
shown are representative of five independent experiments. 
 
Animals 
Male SCID mice, 6-8 weeks old, were obtained from CLEA Japan (Osaka, Japan) and 
maintained under specific pathogen-free conditions. All experiments were performed 
according to the guidelines established by the Tokushima University Committee on Animal 
Care and Use. 
 
Model of multiple-organ metastasis by SBC-5 cells and anti-metastatic effect of 
anti-PTHrP Ab and/or ZOL 
To facilitate the metastasis of SBC-5 cells, SCID mice were depleted of NK cells (22). Briefly, 
each mouse was injected i.p. with TM-β1 monoclonal antibody (300 µg/300 µl PBS/mouse) 
2 days before tumor cell inoculation. Subconfluent SBC-5 cells were harvested and washed 
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with Ca2+- and Mg2+-free PBS. Cell viability was determined by the trypan blue exclusion test, 
and only single cell suspensions of >90% viability were used. Cells (1 x 106 /300 µl) were 
injected into the lateral tail vein of mice on day 0. To determine the optimum timing and 
dosage of ZOL, tumor-bearing mice were treated with i.p. control IgG (300 µg) on days 7, 11, 
14, 18, 21, and 25, i.p. ZOL (2 µg) on days 7, 14, and 21, and intravenous (i.v.) anti-PTHrP 
Ab (200 µg) on days 7, 14, and 21 (14). 
Five weeks after tumor cell inoculation, the mice were anesthetized by i.p. injection 
of pentobarbital (0.5 mg/body), and X-ray photographs of the mice were taken to evaluate 
osteolytic bone metastases; the numbers of osteolytic bone metastases on the X-ray 
photographs were evaluated independently by two investigators (T. Y. and K. I.). The mice 
were sacrificed by cutting the subclavian artery, and the liver and lung were removed. The 
lungs were fixed in Bouin’s solution for 24 h. The number of macroscopic metastatic lesions 
larger than 0.5 mm in diameter in the liver and lung was counted. . 
 
Histology and Immunohistochemical-immunofluorescent analysis 
The hind limbs of the mice were fixed in 10% formalin. Bone specimens were decalcified in 
10% EDTA solution for 1 week and embedded in paraffin. Tissue sections (4 µm thick) were 
processed. For detection of osteoclasts, TRAP staining was performed using a Sigma 
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Diagnostics Acid Phosphatase Kit (Sigma Diagnostics, St. Louis, MO). In vivo cell PTHrP 
production was quantitated using mouse anti-human PTHrP monoclonal antibody (Santa 
Cruz Biotechnology, CA), cell proliferation was quantitiated using mouse anti-human Ki-67 
monoclonal antibody (MIB1, Pharmingen, San Diego, CA), and apoptosis was quantitated 
using the TdT-mediated dUTP-biotin nick end labeling (TUNEL) method. For Ki-67 staining, 
antigen retrieval was performed by boiling in a microwave for 10 min in 0.01 M citrate buffer 
(pH 6.0). The TUNEL assay was performed using the Apoptosis Detection System 
(Promega, Madison, WI) according to the manufacturer’s instructions (23), and in situ   
programmed cell death was assessed by specific labeling of nuclear DNA fragmentation as 
described (24). All sections were also stained with H&E for routine histological 
examinations. 
 
Quantification of immunohistochemistry and immunofluorescence  
The five areas containing the highest numbers of stained cells within a section were selected 
for histologic quantitation by light or fluorescent microscopy with a 200-fold magnification. All 




All data, expressed as means ± SE, were analyzed by one-way analysis of variance. 
Between group differences in the number of metastases to different organs (e.g. bones, 
lungs, liver) were assessed by the Fisher protected least-significant difference test. 
Proliferation index and the numbers of TRAP-positive and apoptotic cells were compared 
using Student’s t test (two-tailed). P values less than 0.05 were considered statistically 
significant. All statistical analyses were performed using StatView ver.5.0. 
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Results  
In vitro effects of anti-PTHrP Ab and/or ZOL on SBC-5 cell proliferation  
We first tested the direct effect of anti-PTHrP Ab and/or ZOL against SBC-5 cells in vitro. As 
previously reported, we again found that anti-PTHrP Ab had no effect on the proliferation of 
SBC-5 cells (14). We also found that neither ZOL alone, at < 10 μg/ml, nor the combination 
of anti-PTHrP Ab nor ZOL at various doses, significantly affected SBC-5 proliferation (Figure 
1).  
 
Effects of ZOL monotherapy on the production of bone metastases in NK-cell 
depleted SCID mice 
SBC-5 cells inoculated intravenously into NK-cell depleted SCID mice produced osteolytic 
bone metastases in the vertebral bone, pelvis scapulae, and hind limbs, as well as in the 
lungs and liver, consistent with our previous reports (14, 18). The mice had micrometastases 
in the bone by 7 days after inoculation (data not shown), experienced paralysis four weeks 
after inoculation, and 30-50% experienced paralysis five weeks after inoculation. We found 
that a single treatment with ZOL on day 7 significantly reduced the formation of bone 
metastases in a dose-dependent manner, but had no effect on the production of metastases 
to visceral organs, such as the lungs and liver (Table 1-A). Administration of up to 2 µg ZOL 
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did not cause a reduction in body weight, suggesting the feasibility of treatment with this 
drug. Based on these results, we used a dose of 2 µg ZOL per mouse in the following 
experiments.  
When we examined the effect of the timing of ZOL monotherapy against bone metastasis, 
we found that earlier administration (i.e., on day 0, 7, or 14) suppressed bone metastases 
(Table 1-B). In contrast, ZOL administered on day 21 (i.e., after the development of 
macroscopic bone metastases) (14) did not reduce the number of bone metastases, 
suggesting that ZOL may suppress the growth of micrometastatic tumor cells in the bone. 
Moreover, ZOL did not inhibit production of visceral metastases, suggesting that this drug 
has limitations as monotherapy against SCLC bone metastasis with multiple organ 
dissemination. Since preliminary experiments showed that repeated treatments with ZOL 
were more effective than a single treatment in inhibiting bone metastases (data not shown), 
we commenced administering ZOL once weekly for three weeks (i.e., on days 7, 14, and 
21).  
 
Effects of combined therapy with anti-PTHrP Ab and ZOL on the production of bone 
metastases in NK-cell depleted SCID mice 
We found that three treatments with ZOL (2 μg) on days 7, 14, and 21 significantly reduced 
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the formation of bone metastases (p<0.05), but again had no effect on metastases to 
visceral organs, such as the lungs and liver. As reported previously (14), three treatments 
with anti-PTHrP Ab (200 μg) on days 7, 14, and 21 also significantly reduced the formation 
of bone metastases (p<0.05), while having no effect on the development of visceral 
metastases. Importantly, three treatments each with PTHrP Ab plus ZOL further inhibited the 
production of bone metastases, while having no effect on visceral metastases (Fig. 2, Table 
2). These results indicate that PTHrP Ab and ZOL each have bone-specific antimetastatic 
effects and that these therapeutic effects were intensified when the two agents are 
combined.  
 
Immunohistochemical and immunofluorescence staining to clarify the anti-bone 
metastatic mechanism of PTHrP Ab and ZOL 
To assess the mechanism by which PTHrP Ab and/or ZOL inhibits bone metastases, we 
performed immunohistochemical and immunofluorescence staining of the bone lesions 
induced by SBC-5 cells. We found that treatment with PTHrP Ab and/or ZOL did not affect 
the production of PTHrP by SBC-5 cells (data not shown) or the number of Ki-67-positive 
proliferating tumor cells (Fig. 3 and 4A). However, treatment with either PTHrP or ZOL 
trended to decrease the number of TRAP-positive cells (osteoclasts), compared with control 
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or control IgG-treated mice. The combination of PTHrP and ZOL further decreased the 
number of osteoclastic cells in bone lesions compared with either agent alone, although the 
differences were not significant (Fig. 3 and 4B). In contrast, the number of apoptotic tumor 
cells (positive for TUNEL) was dramatically increased in the lesions of mice treated with 
either PTHrP Ab or ZOL, and combined treatment increased significantly the number of 
apoptotic tumor cells in bone metastases compared with either agent alone (Fig. 3, 4C, and 
4D). These results suggest that PTHrP Ab and/or ZOL decreased the number of 
tumor-associated osteoclasts and hence induced the apoptosis of tumor cells in bone 
metastases. 
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Discussion    
Molecular interactions between tumor cells and their microenvironments play pivotal roles 
throughout the multiple steps of bone metastasis (25, 26). Once tumor cells adhere to the 
bone microenvironment, they can survive and grow, as well as promote bone destruction. 
Tumor cells produce various factors that increase osteoclast formation, including PTHrP, 
interleukin-6, prostaglandin E2, and tumor necrosis factor. In addition, these cells produce 
various bone resorption-releasing factors, including transforming growth factor-β, insulin-like 
growth factors, bone morphogenetic proteins, platelet-derived growth factor, and fibroblast 
growth factors, which in turn stimulate tumor cells to proliferate and secrete more of the 
factors that increase osteoclast formation (27). PTHrP has prominent effects on bone via its 
interaction with the PTH-1 receptor on osteoblasts. For example, PTHrP has been shown to 
directly regulate the proliferation and differentiation of osteoblasts and to indirectly support 
osteoclastogenesis by upregulating the receptor activator of the NFκB ligand RANKL in 
osteoblasts (27). These findings have suggested that osteoclasts and PTHrP may be 
attractive therapeutic targets to shut off this vicious cycle and hence inhibit bone metastasis.  
We have shown here that the combination of PTHrP Ab and the third generation BP, 
ZOL, inhibit the production of bone metastasis of SCLC to a greater extent than either agent 
alone. The therapeutic effect of these agents, whether as monotherapy or combined, may 
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be predominantly due to the inhibition of osteoclast activation and/or accumulation in bone 
lesions, followed by suppression of bone resorption and induction of tumor-cell apoptosis. 
This is supported by our findings, showing that PTHrP Ab and/or ZOL did not directly inhibit 
the proliferation of SBC-5 cells in vitro and in vivo, and that treatment with PTHrP Ab and/or 
ZOL decreased the number of osteoclasts and increased the number of apoptotic tumor 
cells in bone lesions. Similar results have been observed by treatment of bone metastatic 
lesions with reveromycin A, an inhibitor of isoleucyl-tRNA synthesis that efficiently induces 
the apoptosis of osteoclasts (28). The mechanism by which these agents induce tumor cell 
apoptosis without affecting the number of proliferating tumor cells is unknown at present. 
Further experiments are required to clarify their underlying mechanism.  
Several studies have reported that PTHrP is involved in the resistance to BPs on HHM. 
For example, the rate of response to pamidronate was higher in patients with lower (2-12 
pg/mL) than higher (> 12 pg/mL) blood PTHrP concentrations (29). In addition, the 
emergence of alendronate-refractory HHM was associated with high levels of circulating 
PTHrP (30), further suggesting that PTHrP may play a critical role in intrinsic and/or 
acquired resistance to BPs in bone metastases. Thus, combined treatment with of PTHrP 
Ab and ZOL may control the progression of bone metastases.  
We found, however, that combined therapy with PTHrP Ab and ZOL did not reduce the 
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SBC-5 metastasis to visceral organs, such as the lungs and liver. This finding is consistent 
with our previous reports on PTHrP Ab alone (14) and reveromycin A (28). Using a breast 
cancer model, however, we found that ZOL suppressed lung and liver metastases and 
prolonged overall survival (31), and a recent clinical trial demonstrated that ZOL inhibited 
visceral metastases and prolonged survival of patients with breast cancer (32). While the 
reasons for these discrepancies are unclear, the effects of ZOL may be dependent on the 
types of cancer cells as well as on organ microenvironments. If visceral metastases of lung 
cancer are refractory to ZOL monotherapy as shown here, a combination with other agents, 
such as conventional chemotherapy, may suppress the progression of visceral metastases 
and hence prolong survival.  
In conclusion, we have shown here that the combination of PTHrP Ab and ZOL 
successfully inhibited the production of bone metastases of human SCLC SBC-5 cells 
expressing PTHrP in NK-cell depleted SCID mice, suggesting that this novel dual targeting 
therapy may be useful in controlling bone metastases in a subpopulation of SCLC patients. 
In contrast, this combination therapy did not inhibit the progression of visceral metastases. 
Combination with additional agents, including conventional chemotherapy, may therefore 
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Table 1. Effect of ZOL on multiple organ metastases produced by SBC-5 cells in NK-cell depleted SCID mice. 
A     ZOL        Number        Number of Metastases †  
(μg)         of mice   Bone                Liver                Lung 
Control 5      7 (4-11) 47 (20-56) 59 (57-96)       
0.2  5 6 (4-7)  37 (25-65)       70 (47-104) 
0.6  5 4 (0-3) **  42(28-70)     60 (25-98)      
2  5  3 (0-3) *** 44 (14-63)  65 (16-75)      
B    Day of       Number   Number of metastases † 
treatment     of mice  Bone                Liver                Lung 
Control        5 3 (0-6)  11 (5-18)      93 (28-118)  
Day 0         5  1 (0-2) ** 10 (2-20)  93 (66-110)   
Day 7         5 1 (0-2) *   10 (2-16)   64 (39-119)  
Day 14        5 2 (0-2) * 11 (6-24)  68 (12-97)   
Day 21        5 3 (0-5) *  10 (3-24)   74 (32-122)     
 
A: SBC-5 cells (1 x 106 cells/mouse) were injected into the lateral tail veins of NK cell-depleted SCID mice on day 0, and various 
doses of ZOL were injected intraperitoneally on day 7. The mice were sacrificed on day 35 and the production of metastasis was 
evaluated. B: SBC-5 cells (1 x 106 cells/mouse) were injected into the lateral tail veins of NK cell-depleted SCID mice on day 0, and 
ZOL (2μg) was injected intraperitoneally on the indicated day. The mice were sacrificed on day 35 and the production of metastasis 
was evaluated. † Values are the median (minimum-maximum). Data shown are representative of two independent experiments with 
similar results. * p<0.05, ** p<0.01, *** p<0.001, compared with the control group (Mann-Whitney U test).  
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Table 2. Therapeutic effect of injection with PTHrP Ab and ZOL on multiple organ metastases by SBC-5 cells in NK cell-depleted 
SCID mice   
 
Treatment     Number         Number of Metastases † 
  of mice   Bone                 Liver                 Lung 
 
Control           5         12 (10-13)  24 (12-32)         84 (22-132) 
Control IgG    5       10 (7-11)    26 (12-41)       83 (66-150) 
PTHrP Ab       5        6 (5-7) *     24 (10-40)      82 (26-142) 
ZOL     5        3 (2-5) *    23 (16-34)       77 (42-85) 
PTHrP Ab+ ZOL  5        1 (0-2) **    21 (10-34)       77 (45-177) 
 
SBC-5 cells (1 x 10
6
 cells/mouse) were injected into the lateral tail veins of NK cell-depleted SCID mice on day 0. Mice were injected 
intraperitoneally with control IgG (300 µg) on days 7, 11, 14, 18, 21, and 25, and with ZOL (2µg) on days 7, 14, and 21, and 
intravenously with PTHrP Ab (200µg) on days 7, 14, and 21. The mice were sacrificed on day 35 and the production of metastases was 
evaluated. † Values are the median (minimum-maximum). Data shown are representative of three independent experiments with similar 
results. * p<0.05, compared with the control group, ** p<0.05, compared with the PTHrP Ab or ZOL group (Mann-Whitney U test). 
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Figure Legends 
Figure 1. Effect of Anti-PTHrP antibody (PTHrP Ab) and zoledronic acid (ZOL) on 
proliferation of the SBC-5 cell line.  
SBC-5 cells (2 x 10
3
/well) plated in 96-well plates were incubated overnight in the 
appropriate medium. The cultures were treated with PTHrP Ab and/or ZOL at the indicated 
concentrations for 72h.  Proliferation of SBC-5 cells was determined by the MTT dye 
reduction method.  Values are the mean ± SDs (error bars) of triplicate cultures.  Data 
shown are representative of five independent experiments with similar results.  
 
Figure 2. Inhibition of bone metastasis by treatment with PTHrP Ab and/or ZOL.  
SBC-5 cells (1 x 106 cells/mouse) were injected into the lateral tail veins of NK cell-depleted 
SCID mice on day 0. Tumor-bearing mice were treated i.p. with control IgG (300 µg) or ZOL 
(2 µg) or i.v. with PTHrP Ab (200 µg) at the indicated times. Five weeks after tumor cell 
inoculation, bone metastases were assessed by X-ray photograph. Arrows, osteolytic bone 
metastases. 
 
Figure 3. Histologic examination of bone metastatic lesions.   
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SBC-5 cells (1 x 10
6
 cells/mouse) were intravenously inoculated into NK cell-depleted SCID 
mice on day 0. Tumor-bearing mice were treated i.p. with control IgG (300 µg) or ZOL (2 µg) 
or i.v. with PTHrP Ab (200 µg) at the indicated times. The mice were sacrificed on day 35, 
and their bone metastatic lesions were harvested and histologically examined. Sections 
were stained with H&E, anti-human PTHrP monoclonal antibody, antibody to Ki-67, TRAP 
and TUNEL.  
 
Figure 4. Quantification of osteoclasts and apoptotic cells in bone lesions.  
(A) Tumor cell proliferation was determined by Ki-67-positive proliferation index (percentage 
of Ki-67-positive cells). (B) Osteoclasts were determined by TRAP staining. (C,D) Apoptotic 
cells were determined by immunofluorescence (C) and by TUNEL staining (D). Columns, 
mean of five areas; bars, SD. *, P < 0.01 compared with the control group; **, P < 0.05 
compared with the PTHrP Ab or ZOL group (Mann-Whitney U test). 
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